AR016510A1 - Derivados arilalquilaminicos calciliticos, una composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de unmedicamento - Google Patents

Derivados arilalquilaminicos calciliticos, una composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de unmedicamento

Info

Publication number
AR016510A1
AR016510A1 ARP980101562A ARP980101562A AR016510A1 AR 016510 A1 AR016510 A1 AR 016510A1 AR P980101562 A ARP980101562 A AR P980101562A AR P980101562 A ARP980101562 A AR P980101562A AR 016510 A1 AR016510 A1 AR 016510A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
substituted
cycloalkyl
ocf3
Prior art date
Application number
ARP980101562A
Other languages
English (en)
Original Assignee
Zimmermann Astrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zimmermann Astrid filed Critical Zimmermann Astrid
Publication of AR016510A1 publication Critical patent/AR016510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/06—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and unsaturated carbon skeleton
    • C07C255/07—Mononitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/17—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/30—Ortho- or ortho- and peri-condensed systems containing three rings containing seven-membered rings
    • C07C2603/32—Dibenzocycloheptenes; Hydrogenated dibenzocycloheptenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados arilalquilamínicos calcilíticos caracterizados porque comprenden un compuesto segun la formula (I) en la que: Y1 es un enlace covalente,alquilenoo alquenileno de hasta 4 átomos de C, no sustituido o sustituido con alquilo C1-4; Y2 esmetile no, no sustituido o sustituido con alquilo C1-4 o CF3; Zse selecciona del grupo formado por un enlace covalente, O, S, NH, N-alquilo C1-4, O(CH2)n, (CH2)nO, NRC=O y C=ONR, donde R es alquilo C1-4 y n es unnumero entero de 1 a 3; R3 y R4 son,independ ientemente, metilo o etilo, o juntos forman ciclopropilo; R5 es fenilo o naftilo, no sustituido o sustituido conuno o más sustituyentes seleccionados del grupo formado por OH, alquilo C1-4, CH(CH3)2, halo, halo-alquilo C1-4, alcoxi C1-4,cicloalquilo C3-6, OSO2RIV, CN,NO2, OCF3, CF3 y CH2CF3, donde RIV representa alquilo C1-4 o cicloalquilo C3-6; G es un enlace covalente o C-R6, donde R6 es H, OH u O (formando un restocarbonilo); R7 es H, OH u O-alquilo C1-4; R8 es H o alquilo C1-4;o R7 y R8 ju ntos forman un resto carbonilo; el resto -A-B- representa CH2CH2, un enlacecovalente, -CH=CH- o -C:::C-;y X se selecciona del grupo formado por las subformulas (Ia) a (Ie) donde:en la subformula (Ia): W se selecciona del grupoformadopor R1, SO2R1, C (O)R1, SO2NR1R1, C(O)NR1R1, C(O)OR1SO3R1, donde R1 y R1 se seleccionan independientemente del grupo formado por hidrogeno, alquilo C1-4,cicloalquilo C3-6, alquenilo C2-5, alquinilo C2-5, heterocicloalquilarilo y aril-alquiloC1-4; o R1 y R1 juntos fo rman un anillo heterocíclico de 3 a 7miembros, opcionalmente sustituido; donde cualquier sustituyente se selcciona del grupo formado por CN, arilo, CO2R, CO2NHR, OH, OR, NH2, halo, CF3, OCF3 yNO2, donde R representa alquiloC1-4 o cicloalquilo C3-6; X1 se selecciona del grupo formado por CN, NO2, Cl, F, Br, I, H, R, OR, CF3, OCF3 y OSO2R, dondeR representa alquilo C1-4 o cicloalquilo C3-6; X2, X3 y X4, independientemente, se seleccionan del grupo formado por CN, NO2,Cl, F, Br, I, H, R, OR, CF3, OCF3 o OSO2R, donde R representa alquilo o haloalquilo C1-4; o X1 y X2 juntos forman un anillo arílico o heteroarílico, sustituido o no sustituido; donde
ARP980101562A 1997-04-08 1998-04-08 Derivados arilalquilaminicos calciliticos, una composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de unmedicamento AR016510A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4272497P 1997-04-08 1997-04-08
US6133397P 1997-10-08 1997-10-08
US6133097P 1997-10-08 1997-10-08
US6132797P 1997-10-08 1997-10-08
US6133197P 1997-10-08 1997-10-08
US6132997P 1997-10-08 1997-10-08

Publications (1)

Publication Number Publication Date
AR016510A1 true AR016510A1 (es) 2001-07-25

Family

ID=27556439

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980101562A AR016510A1 (es) 1997-04-08 1998-04-08 Derivados arilalquilaminicos calciliticos, una composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de unmedicamento

Country Status (24)

Country Link
US (1) US6294531B1 (es)
EP (1) EP0973730B1 (es)
JP (1) JP2001523223A (es)
KR (1) KR20010006113A (es)
CN (1) CN1259120A (es)
AR (1) AR016510A1 (es)
AT (1) ATE269300T1 (es)
AU (1) AU721910B2 (es)
BR (1) BR9808491A (es)
CA (1) CA2286454A1 (es)
CO (1) CO4950536A1 (es)
DE (1) DE69824566T2 (es)
DZ (1) DZ2461A1 (es)
ES (1) ES2223126T3 (es)
HU (1) HUP0001494A3 (es)
IL (1) IL132205A0 (es)
NO (1) NO994877L (es)
NZ (1) NZ500055A (es)
PE (1) PE69299A1 (es)
PL (1) PL336097A1 (es)
TR (1) TR199902516T2 (es)
TW (1) TW407144B (es)
UY (1) UY24949A1 (es)
WO (1) WO1998045255A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
UA71586C2 (en) * 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
AU750584B2 (en) * 1999-02-17 2002-07-25 Merck & Co., Inc. Dibenzo-azepine derivatives as alphav integrin receptor antagonists
JP2001026506A (ja) * 1999-04-28 2001-01-30 Takeda Chem Ind Ltd スルホンアミド誘導体
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2002012189A1 (fr) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Composes amide bicycliques condenses et utilisations medicales associees
AU2001277752A1 (en) 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
AU2002230579A1 (en) * 2000-10-25 2002-05-06 Smithkline Beecham Corp Calcilytic compounds
US7176322B2 (en) 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
DK1619180T3 (da) 2003-04-23 2010-03-29 Japan Tobacco Inc CaSR-antagonist
JPWO2004106280A1 (ja) * 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
RS52715B (en) 2005-04-13 2013-08-30 Astex Therapeutics Limited HYDROXYBENZAMIDE DERIVATIVES AND THEIR APPLICATIONS AS HSP90 INHIBITORS
WO2007056388A2 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2081891A2 (en) 2006-10-12 2009-07-29 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
BRPI0721700A2 (pt) 2007-05-29 2013-02-13 Shanghai Inst Materia Medica usos de compostos heptacÍclicos, os referidos compostos, e composiÇÕes compreendendo os mesmos
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN116574039A (zh) * 2023-05-17 2023-08-11 上海大学 一种多取代胺基苯甲腈类化合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE298506C (es)
GB1199632A (en) * 1967-09-07 1970-07-22 Ici Ltd Alkanolamine Derivatives
GB1199037A (en) 1967-09-27 1970-07-15 Ici Ltd Alkanolamine Derivatives
US4165384A (en) 1974-11-01 1979-08-21 Aktiebolaget Hassle Amide substituted phenoxy propanol amines
CA1262729A (en) * 1983-10-19 1989-11-07 Leo Alig Phenoxypropanolamines
US5166218A (en) * 1983-10-19 1992-11-24 Hoffmann-La Roche Inc. Phenoxypropanolamines and pharmaceutical compositions thereof
DD298506A5 (de) * 1988-12-30 1992-02-27 Ernst-Moritz-Arndt-Universitaet Greifswald,De Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole
DE4017019A1 (de) * 1990-05-26 1991-11-28 Hoechst Ag Verwendung von substituierten ss-hydroxyethylaminen als potente hemmstoffe der exoenzyme von pilzen
EP0901459B1 (en) * 1996-04-09 2005-06-29 Nps Pharmaceuticals, Inc. Calcilytic compounds

Also Published As

Publication number Publication date
TR199902516T2 (xx) 2000-02-21
CA2286454A1 (en) 1998-10-15
AU6890098A (en) 1998-10-30
IL132205A0 (en) 2001-03-19
NO994877D0 (no) 1999-10-07
PE69299A1 (es) 1999-09-26
PL336097A1 (en) 2000-06-05
TW407144B (en) 2000-10-01
ATE269300T1 (de) 2004-07-15
KR20010006113A (ko) 2001-01-26
ES2223126T3 (es) 2005-02-16
JP2001523223A (ja) 2001-11-20
AU721910B2 (en) 2000-07-20
EP0973730A4 (en) 2000-08-23
DZ2461A1 (fr) 2003-01-18
HUP0001494A2 (hu) 2000-10-28
UY24949A1 (es) 2001-04-30
NZ500055A (en) 2001-12-21
EP0973730B1 (en) 2004-06-16
US6294531B1 (en) 2001-09-25
EP0973730A1 (en) 2000-01-26
CO4950536A1 (es) 2000-09-01
DE69824566D1 (de) 2004-07-22
HUP0001494A3 (en) 2002-01-28
CN1259120A (zh) 2000-07-05
DE69824566T2 (de) 2005-08-18
BR9808491A (pt) 2000-05-23
NO994877L (no) 1999-10-07
WO1998045255A1 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
AR016510A1 (es) Derivados arilalquilaminicos calciliticos, una composicion farmaceutica que los comprende y el uso de dichos derivados para la manufactura de unmedicamento
AR014975A1 (es) Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR044909A1 (es) Derivados de tiazolilpiperidina, procesos para su preparacion, composiciones farmaceuticas que los comprenden y aplicaciones de dichos derivados en el tratamiento de hipertrigliceridemia , hipercolesterolemia y dislipidemia
AR057244A1 (es) Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes.
AR050181A1 (es) Derivados de urea ciclicos sustituidos, su preparacion y su uso farmaceutico como inhibidores de quinasa
PT1289955E (pt) Piperidinas para utilizacao como antagonistas dos receptores da orexina
AR032453A1 (es) Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos
CY1111075T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν τα παραγωγα της 3-αμινο-αζετιδινης, τα νεα παραγωγα τους και η προετοιμασια τους
AR050267A1 (es) Derivados de urea ciclicos sustituidos con heterociclo, su preparacion y su uso farmaceutico como inhibidores de quinasa
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
ECSP067013A (es) 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4
AR049418A1 (es) Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
AR047008A1 (es) Compuestos de 4-tetrazolil-4-fenilpiperidina como agonistas de los receptores opioides y agentes terapeuticos de utilidad para el tratamiento del dolor y composiciones farmaceuticas que los contienen como principio activo en combinacion con otros agentes terapéuticos.
CY1106858T1 (el) Νεα παραγωγα κυκλικου αμιδιου
RS50672B (sr) Postupak za pripremanje n-fenilpirazol-1-karboksamida
AR038883A1 (es) Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos
CO5031246A1 (es) Compuestos calciliticos
ES2092651T3 (es) Derivados heterociclicos diazotados n-sustituidos por un grupo bifenilmetilo, su preparacion, las composiciones farmaceuticas que los contienen.
SE9703377D0 (sv) New compounds
AR050963A1 (es) Derivados bis-azaindolicos, su utilizacion farmaceutica como inhibidores de cinasas y su uso en la fabricacion de medicamentos para el tratamiento de los canceres.
CO5570679A2 (es) Compuestos heterociclicos para el uso en el tratamiento de los transtornos de las vias urinarias
AR006793A1 (es) Compuestos pirazol o sus sales y herbicidas conteniendo los mismos
AR036602A1 (es) Agonistas muscarinicos
CO5650231A2 (es) Derivados de 1-(alquilaminoalquil-pirrolidin-/piperidinil)-2,2-difenilacetamida como antagonistas del receptor muscarinico, su procedimiento de sintesis y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal